|
ACEI
|
Angiotensin Converting Enzyme inhibitors
|
|
ACR/VF
|
American College of
Rheumatology/Vasculitis Foundation
|
|
Adolopment
|
Adoption-Adaptation-Development
|
|
AGREE II
|
Appraisal of Guidelines for Research and
Evaluation Instrument
|
|
Anti-TNF α
|
Anti-tumor necrosis factor alpha
|
|
ARB
|
Angiotensin Receptor Blocker
|
|
ASA
|
Acetyl salicylic acid
|
|
AST
|
Aspartate aminotransferase
|
|
ALT
|
Alanine Transaminase
|
|
ANA
|
Antinuclear Antibodies
|
|
ANCA
|
Antineutrophil cytoplasm antibodies
|
|
BB
|
Beta Blocker
|
|
BCG
|
Bacille Calmette Guerin
|
|
C3
|
Complement 3
|
|
CAA
|
Coronary artery aneurysm
|
|
CABG
|
Coronary artery bypass graft
|
|
CAL
|
Coronary artery lesion
|
|
CDC
|
Center of Disease Control
|
|
CHF
|
Congestive Heart Failure
|
|
CKD
|
Complete Kawasaki Disease
|
|
CNS
|
Central Nervous System
|
|
COVID 19
|
Coronavirus disease 2019
|
|
CPG
|
Clinical Practice Guideline
|
|
CRP
|
C- reactive protein
|
|
CTA
|
Computed Tomographic angiography
|
|
DHS
|
Demographic and Health Survey
|
|
DMARDs
|
Disease Modifying
Anti-Rheumatic Drugs
|
|
DOACs
|
Direct oral anticoagulants
|
|
EBV
|
Epstein Bar virus
|
|
EPG
|
Egyptian Pediatrics Clinical Practice
Guidelines Committee
|
|
EPG CPG
|
EPG Clinical Practice Guideline
|
|
ERG
|
External Review Group
|
|
ESR
|
Erythrocyte Sedimentation Rate
|
|
GAG
|
Guideline Adaptation Group
|
|
GDG
|
Guideline Development Group
|
|
GPS
|
Good Practice Statement
|
|
GU
|
Genitourinary
|
|
GRADE
|
Grading of Recommendations Assessment,
Development and Evaluation
|
|
GI
|
Gastrointestinal
|
|
Hs
|
High sensitivity
|
|
HPF
|
High power field
|
|
IKD
|
Incomplete Kawasaki Disease
|
|
IVIG
|
Intravenous immunoglobulins
|
|
JCS
|
Japanese circulation society
|
|
JSCS
|
Japanese Society of Cardiovascular surgery
|
|
KD
|
Kawasaki Disease
|
|
KDSS
|
Kawasaki disease Shock Syndrome
|
|
LDA
|
Low dose Aspirin
|
|
LVEF
|
Left ventricular Ejection Fraction
|
|
LVSF
|
Left Ventricular Shortening Fraction
|
|
MAS
|
Macrophage activation syndrome
|
|
MIS-C
|
Multisystem inflammatory syndrome in
children
|
|
MP
|
Methylprednisolone
|
|
MRI
|
Magnetic resonance imaging
|
|
NHS
|
The National Health Service
|
|
NSTE-ACS
|
non–ST-segment–elevation acute
coronary syndrome;
|
|
NT-proBNP
|
N-terminal prohormones of brain
natriuretic peptide
|
|
PAN
|
Polyarteritis Nodosa
|
|
PCI
|
Percutaneous coronary
intervention
|
|
PCR
|
Polymerase chain reaction
|
|
PICO
|
Population, intervention, comparison, and
outcomes
|
|
|
Patient
population, intervention, Professional, outcomes, and healthcare context
|
|
RIGHT
|
A Reporting Tool for Practice Guidelines
in Health Care
|
|
SARS COV2
|
Severe Acute Respiratory syndrome corona
virus 2
|
|
SHARE
|
Single Hub and Access point for pediatric
Rheumatology in Europe
|
|
SIP
|
Societa Italiana Di Pediatria (Italian
Society of Pediatrics)
|
|
STEMI
|
ST-segment–elevation
myocardial infarction
|
|
TEE
|
Transesophageal echocardiography
|
|
TNF
|
Tumor necrosis factor
|
|
tPA
|
Tissue-type plasminogen activator
|
|
WBC
|
White Blood Cell Count
|
